GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alpha Tau Medical DRTS · USD

Health Care · US listing · 🇺🇸 United States

Compare

14.11

+2.84%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Alpha Tau Medical

Its shares trade under the ticker DRTS. It has been listed since 8 March 2022.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The firm has one subsidiary Healthcare Capital Corp.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
8 Mar 2022
Employees
121
Head office
KIRYAT HAMADA 5, JERUSALEM, L3, 9777605
Incorporated in
L3
Classification
Surgical & Medical Instruments & Apparatus
Filer status
Accelerated filer<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Uzi SoferChairman of the Board, Chief Executive Officer, since 2015
  • Mr. Raphi LevyChief Financial Officer
  • Mr. Amnon GatChief Operations Officer
  • Mr. Ronen SegalChief Technology Officer
  • Prof. Yona KeisariChief Scientific Officer
  • Dr. Robert DenChief Medical Officer
  • Prof. Itzhak KelsonChief Physics Officer
  • Ms. Ruth AlonDirector
  • DR. David MilchDirector
  • Ms. Maya NetserDirector
  • Mr. Alan AdlerIndependent Director
  • Mr. Michael AvruchIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company is clinical-stage oncology therapeutics with technology using alpha particles for tumor treatment.
  • Technology enables precise delivery of radium-224 to damage cancer cells within tumors.
  • Operates with 121 employees and has a subsidiary Healthcare Capital Corp.

Weaknesses

  • Company is clinical-stage, indicating early development phase with unproven commercial viability.
  • Relies on a single technology (alpha particle diffusion) for tumor treatment.
  • IPO occurred in 2022, suggesting limited market history and potential financial instability.

Opportunities

  • Growing demand for targeted cancer therapies could increase market opportunities.
  • Potential for expansion into new oncology treatments using alpha radiation technology.
  • Subsidiary Healthcare Capital Corp. may provide financial or strategic support.

Threats

  • Clinical-stage companies face high failure rates in drug development and regulatory approval.
  • Dependence on a single technology may limit adaptability to market changes.
  • Regulatory hurdles and competition in the oncology therapeutics sector pose significant risks.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.